Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

by B2i | Feb 13, 2024 | Press Releases

ROCKVILLE, Md., Feb. 13, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“SHPH” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

by B2i | Jan 23, 2024 | Press Releases

ROCKVILLE, Md., Jan. 23, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

by B2i | Jan 8, 2024 | Press Releases

ROCKVILLE, Md., Jan. 8, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced they have received the ‘Safe to Proceed’ letter from the U.S. Food and Drug Administration (FDA) for the...

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

by B2i | Dec 11, 2023 | Press Releases

ROCKVILLE, Md., Dec. 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next...

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

by B2i | Nov 30, 2023 | Press Releases

Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md., Nov. 30, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...